Condition
Early Alzheimer's Disease clinical trials and research
Research outlook What's coming for Alzheimer's disease: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 5 Early Alzheimer's Disease clinical trials that are recruiting, at sites in 13 countries (most in South Korea (2), United States (2), China (1)). By phase: Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 13Countries
Newest Early Alzheimer's Disease clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement | — | Prague | Recruiting | Sep 25, 2026 |
| Stem Cells plus monoclonal antibodies for mild cognitive impairment or early Alzheimer's disease | Phase 2 | Miami, Florida | Recruiting | Apr 6, 2026 |
| L. lactis CKDB001 for people with early Alzheimer's disease | — | Gyeonggi-do and 1 other locations | Recruiting | Mar 27, 2026 |
| TTYP01 tablets for people with early symptomatic Alzheimer's disease | Phase 2 | Chongqing, Chongqing Municipality | Recruiting | Nov 26, 2025 |
| MK-2214 for people with early Alzheimer's disease | Phase 2 | Irvine, California and 79 other locations | Recruiting | Jun 24, 2025 |
All recruiting trials (5)
-
Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement
This trial tests whether taking urolithin A in addition to standard care helps people with early Alzheimer’s or mild cognitive impairment show better biomarkers and cognition.
-
Stem Cells plus monoclonal antibodies for mild cognitive impairment or early Alzheimer's disease
This study tests whether one infusion of human mesenchymal stem cells added to standard antibody therapy can slow cognitive and daily-living decline in people with mild Alzheimer's or mild cognitive impairment who are already on approved antibody treatment.
-
L. lactis CKDB001 for people with early Alzheimer's disease
This 24-week study will test if oral L. lactis CKDB001 helps adults aged 55–85 with early Alzheimer's disease and positive amyloid PET compared with a placebo.
-
TTYP01 tablets for people with early symptomatic Alzheimer's disease
This study will test whether two doses of TTYP01 tablets (60 mg and 90 mg) help people aged 60–85 with early symptomatic Alzheimer's disease (MCI due to AD or mild AD dementia) compared with placebo.
-
MK-2214 for people with early Alzheimer's disease
This trial will test whether the drug MK-2214 can slow the spread of tau protein in the brains of people with mild cognitive impairment or mild dementia from Alzheimer's disease.
Related topics
Quick answers
How many Early Alzheimer's Disease clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 13 countries. The most sites are in South Korea (2 trials), United States (2 trials), China (1 trial), Czechia (1 trial), Argentina (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.